|
1
|
Aloia MS, Arnedt JT, Davis JD, Riggs RL
and Byrd D: Neuropsychological sequelae of obstructive sleep
apnea-hypopnea syndrome: A critical review. J Int Neuropsychol Soc.
10:772–785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Golbin JM, Somers VK and Caples SM:
Obstructive sleep apnea, cardiovascular disease, and pulmonary
hypertension. Proc Am Thorac Soc. 5:200–206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Olson EJ, Moore WR, Morgenthaler TI, Gay
PC and Staats BA: Obstructive sleep apnea-hypopnea syndrome. Mayo
Clinic Proceedings. Elsevier; pp. 1545–1552. 2003, View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pihtili A, Bingol Z, Kiyan E, Cuhadaroglu
C, Issever H and Gulbaran Z: Obstructive sleep apnea is common in
patients with interstitial lung disease. Sleep Breathing.
17:1281–1288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Redline S, Yenokyan G, Gottlieb DJ, Shahar
E, O'Connor GT, Resnick HE, Diener-West M, Sanders MH, Wolf PA,
Geraghty EM, et al: Obstructive sleep apnea-hypopnea and incident
stroke: The sleep heart health study. Am J Respir Crit Care Med.
182:269–277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yaggi HK, Concato J, Kernan WN, Lichtman
JH, Brass LM and Mohsenin V: Obstructive sleep apnea as a risk
factor for stroke and death. N Engl J Med. 353:2034–2041. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Punjabi NM: The epidemiology of adult
obstructive sleep apnea. Proc Am Thorac Soc. 5:136–143. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Young T, Palta M, Dempsey J, Skatrud J,
Weber S and Badr S: The occurrence of sleep-disordered breathing
among middle-aged adults. N Engl J Med. 328:1230–1235. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campos-Rodriguez F, Martinez-Garcia MA,
Martinez M, Duran-Cantolla J, Peña Mde L, Masdeu MJ, Gonzalez M,
Campo FD, Gallego I, Marin JM, et al: Association between
obstructive sleep apnea and cancer incidence in a large multicenter
Spanish cohort. Am J Respir Crit Care Med. 187:99–105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kendzerska T, Leung RS, Hawker G,
Tomlinson G and Gershon AS: Obstructive sleep apnea and the
prevalence and incidence of cancer. CMAJ. 186:985–992. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martínez-García MA, Campos-Rodriguez F,
Durán-Cantolla J, de la Peña M, Masdeu MJ, González M, Del Campo F,
Serra PC, Valero-Sánchez I, Ferrer MJ, et al: Obstructive sleep
apnea is associated with cancer mortality in younger patients.
Sleep Med. 15:742–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma Y, Hou L, Yu F, Lu G, Qin S, Xie R,
Yang H, Wu T, Luo P, Chai L, et al: Incidence and physiological
mechanism of carboplatin-induced electrolyte abnormality among
patients with non-small cell lung cancer. Oncotarget.
8:18417–18423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Y, Song X, Wang X, Wei L, Liu X, Yuan
S and Lv L: Effect of chronic intermittent hypoxia on biological
behavior and hypoxia-associated gene expression in lung cancer
cells. J Cell Biochem. 111:554–563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almendros I, Montserrat JM, Ramirez J,
Torres M, Duran-Cantolla J, Navajas D and Farré R: Intermittent
hypoxia enhances cancer progression in a mouse model of sleep
apnoea. Eur Respir J. 39:215–217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Almendros I, Montserrat JM, Torres M,
Dalmases M, Cabañas ML, Campos-Rodríguez F, Navajas D and Farré R:
Intermittent hypoxia increases melanoma metastasis to the lung in a
mouse model of sleep apnea. Respir Physiol Neurobiol. 186:303–307.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Almendros I, Wang Y, Becker L, Lennon FE,
Zheng J, Coats BR, Schoenfelt KS, Carreras A, Hakim F, Zhang SX, et
al: Intermittent hypoxia-induced changes in tumor-associated
macrophages and tumor malignancy in a mouse model of sleep apnea.
Am J Respir Crit Care Med. 189:593–601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Toffoli S and Michiels C: Intermittent
hypoxia is a key regulator of cancer cell and endothelial cell
interplay in tumours. FEBS. 275:2991–3002. 2008. View Article : Google Scholar
|
|
18
|
Verduzco D, Lloyd M, Xu L, Ibrahim-Hashim
A, Balagurunathan Y, Gatenby RA and Gillies RJ: Intermittent
hypoxia selects for genotypes and phenotypes that increase
survival, invasion, and therapy resistance. PLoS One.
10:e01209582015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lassalle P, Molet S, Janin A, Heyden JV,
Tavernier J, Fiers W, Devos R and Tonnel AB: ESM-1 is a novel human
endothelial cell-specific molecule expressed in lung and regulated
by cytokines. J Biol Chem. 271:20458–20464. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JH, Park MY, Kim CN, Kim KH, Kang HB,
Kim KD and Kim JW: Expression of endothelial cell-specific
molecule-1 regulated by hypoxia inducible factor-1α in human colon
carcinoma: Impact of ESM-1 on prognosis and its correlation with
clinicopathological features. Oncol Rep. 28:1701–1708. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu N, Zhang LH, Du H, Hu Y, Zhang GG,
Wang XH, Li JY and Ji JF: Overexpression of endothelial cell
specific molecule-1 (ESM-1) in gastric cancer. Ann Surg Oncol.
17:2628–2639. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarrazin S, Adam E, Lyon M, Depontieu F,
Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P and
Delehedde M: Endocan or endothelial cell specific molecule-1
(ESM-1): A potential novel endothelial cell marker and a new target
for cancer therapy. Biochim Biophys Acta. 1765:25–37.
2006.PubMed/NCBI
|
|
23
|
Kang YH, Ji NY, Lee CI, Lee HG, Kim JW,
Yeom YI, Kim DG, Yoon SK, Kim JW, Park PJ and Song EY: ESM-1
silencing decreased cell survival, migration, and invasion and
modulated cell cycle progression in hepatocellular carcinoma. Amino
Acids. 40:1003–1013. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun H, Zhang H, Li K, Wu H, Zhan X, Fang
F, Qin Y and Wei Y: ESM-1 promotes adhesion between monocytes and
endothelial cells under intermittent hypoxia. J Cell Physiol.
234:1512–1521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan LF, Diao LM, Chen DJ, Liu MQ, Zhu LQ,
Li HG, Tang ZJ, Xia D, Liu X and Chen HL: Expression of HIF-1 alpha
and its relationship to apoptosis and proliferation in lung cancer.
Ai Zheng. 21:254–258. 2002.(In Chinese). PubMed/NCBI
|
|
26
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation
of hypoxia inducible factor 1 alpha and 2 alpha in operable
non-small cell lung cancer to angiogenic/molecular profile of
tumours and survival. Br J Cancer. 85:881–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Swinson DE, Jones JL, Cox G, Richardson D,
Harris AL and O'Byrne KJ: Hypoxia-inducible factor-1 alpha in non
small cell lung cancer: Relation to growth factor, protease and
apoptosis pathways. Int J Cancer. 111:43–50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leroy X, Aubert S, Zini L, Franquet H,
Kervoaze G, Villers A, Delehedde M, Copin MC and Lassalle P:
Vascular endocan (ESM-1) is markedly overexpressed in clear cell
renal cell carcinoma. Histopathology. 56:180–187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Diepenbruck M and Christofori G:
Epithelial-mesenchymal transition (EMT) and metastasis: Yes, no,
maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guarino M: Epithelial-mesenchymal
transition and tumour invasion. Int J Biochem Cell Biol.
39:2153–2160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wong IY, Javaid S, Wong EA, Perk S, Haber
DA, Toner M and Irimia D: Collective and individual migration
following the epithelial-mesenchymal transition. Nat Mater.
13:1063–1071. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liao D and Johnson RS: Hypoxia: A key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song X, Liu X, Chi W, Liu Y, Wei L, Wang X
and Yu J: Hypoxia-induced resistance to cisplatin and doxorubicin
in non-small cell lung cancer is inhibited by silencing of
HIF-1alpha gene. Cancer Chemother Pharmacol. 58:776–784. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garay T, Juhász É, Molnár E, Eisenbauer M,
Czirók A, Dekan B, László V, Hoda MA, Döme B, Tímár J, et al: Cell
migration or cytokinesis and proliferation? -revisiting the ‘go or
grow’ hypothesis in cancer cells in vitro. Exp Cell Res.
319:3094–3103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Grayson WL, Zhao F, Bunnell B and Ma T:
Hypoxia enhances proliferation and tissue formation of human
mesenchymal stem cells. Biochem Biophys Res Commun. 358:948–953.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meininger CJ, Schelling ME and Granger HJ:
Adenosine and hypoxia stimulate proliferation and migration of
endothelial cells. Am J Physiol. 255:H554–H562. 1988.PubMed/NCBI
|
|
37
|
Teicher BA: Hypoxia and drug resistance.
Cancer Metastasis Rev. 13:139–168. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rohwer N and Cramer T: Hypoxia-mediated
drug resistance: Novel insights on the functional interaction of
HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nishio K, Nakamura T, Koh Y, Suzuki T,
Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin
Oncol. 11:109–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen C, Nettleton D, Jiang M, Kim SK and
Powell-Coffman JA: Roles of the HIF-1 hypoxia-inducible factor
during hypoxia response in Caenorhabditis elegans. J Biol Chem.
280:20580–20588. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hänze J, Eul BG, Savai R, Krick S, Goyal
P, Grimminger F, Seeger W and Rose F: RNA interference for
HIF-1alpha inhibits its downstream signalling and affects cellular
proliferation. Biochem Biophys Res Commun. 312:571–577. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jin H, Rugira T, Ko YS, Park SW, Yun SP
and Kim HJ: ESM-1 Overexpression is involved in increased
tumorigenesis of radiotherapy-resistant breast cancer cells.
Cancers (Basel). 12:13632020. View Article : Google Scholar
|
|
44
|
Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan
G and Jiang Y: HULC long noncoding RNA silencing suppresses
angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling
pathway in human gliomas. Oncotarget. 7:14429–14440. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Campillo N, Torres M, Vilaseca A, Nonaka
PN, Gozal D, Roca-Ferrer J, Picado C, Montserrat JM, Farré R,
Navajas D and Almendros I: Role of Cyclooxygenase-2 on intermittent
hypoxia-induced lung tumor malignancy in a mouse model of sleep
apnea. Sci Rep. 7:446932017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kang HS, Kwon HY, Kim IK, Ban WH, Kim SW,
Kang HH, Yeo CD and Lee SH: Intermittent hypoxia exacerbates tumor
progression in a mouse model of lung cancer. Sci Rep. 10:18542020.
View Article : Google Scholar : PubMed/NCBI
|
